Keros Therapeutics's top three insider shareholders as of May 14, 2026 are Management 4 G.P. (2015) Ltd. Pontifax (TenPercentOwner, 1.23Mn shares), Ran Nussbaum (Director, 1.23Mn shares), Management 4 G.P. (2015) Ltd. Pontifax (TenPercentOwner, 1.23Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Ran Nussbaum | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Tomer Kariv | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Ran Nussbaum | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Management 4 G.P. (2015) Ltd. Pontifax | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Ran Nussbaum | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Management 4 G.P. (2015) Ltd. Pontifax | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Management 4 G.P. (2015) Ltd. Pontifax | - | 0 | 1,226,412 | 30 Nov, 2022 |
| Jasbir Seehra | Chief Executive Officer | 440,708 | 0 | 06 Apr, 2026 |
| Julius Knowles | - | 0 | 102,233 | 18 Dec, 2025 |
| Julius Knowles | - | 0 | 102,233 | 18 Dec, 2025 |
| Julius Knowles | - | 0 | 102,233 | 18 Dec, 2025 |
| Jennifer Lachey | Chief Scientific Officer | 95,100 | 0 | 19 Jul, 2022 |
| Jennifer Lachey | Chief Scientific Officer | 95,100 | 0 | 19 Jul, 2022 |
| Jennifer Lachey | Chief Scientific Officer | 95,100 | 0 | 19 Jul, 2022 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 0 | 19 Feb, 2025 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 0 | 19 Feb, 2025 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 0 | 19 Feb, 2025 |
| Carl L Gordon | - | 0 | 45,057 | 18 Dec, 2025 |
| Yung H. Chyung | Chief Medical Officer | 44,000 | 0 | 19 Feb, 2025 |
| Esther Cho | Svp, General Counsel | 39,755 | 0 | 20 Feb, 2026 |
| Keith Regnante | Chief Financial Officer | 39,261 | 0 | 20 Feb, 2026 |
| Keith Regnante | Chief Financial Officer | 39,261 | 0 | 20 Feb, 2026 |
| Lorena Raquel Lerner | Chief Science Officer | 31,127 | 0 | 20 Feb, 2026 |
| Lorena Raquel Lerner | Chief Science Officer | 31,127 | 0 | 20 Feb, 2026 |
| Lorena Raquel Lerner | Chief Science Officer | 31,127 | 0 | 20 Feb, 2026 |
| Charles W. Newton | - | 13,215 | 0 | 11 Mar, 2026 |
| Charles W. Newton | - | 13,215 | 0 | 11 Mar, 2026 |
| Charles W. Newton | - | 13,215 | 0 | 11 Mar, 2026 |
| Jean Jacques Bienaime | - | 8,450 | 0 | 17 Apr, 2026 |
| Julius Knowles | - | 6,441 | 0 | 06 Jun, 2025 |
| Julius Knowles | - | 6,441 | 0 | 06 Jun, 2025 |
| Julius Knowles | - | 6,441 | 0 | 06 Jun, 2025 |
| Nima Farzan | - | 5,250 | 0 | 06 Jun, 2025 |
| Ran Nussbaum | - | 5,250 | 0 | 06 Jun, 2025 |
| Alpna Seth | - | 5,250 | 0 | 06 Jun, 2025 |
| Alpna Seth | - | 5,250 | 0 | 06 Jun, 2025 |
| Carl L Gordon | - | 5,250 | 0 | 06 Jun, 2025 |
| Ran Nussbaum | - | 5,250 | 0 | 06 Jun, 2025 |
| Ran Nussbaum | - | 5,250 | 0 | 06 Jun, 2025 |
| Tomer Kariv | - | 5,250 | 0 | 06 Jun, 2025 |
| Mary Ann Gray | - | 5,250 | 0 | 06 Jun, 2025 |
| Alpna Seth | - | 5,250 | 0 | 06 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 15 Apr, 2026 | Jean Jacques Bienaime | Common Stock | A | 1,000 | $11.70 | 8,450 | D | P |
| 02 Apr, 2026 | Jasbir Seehra | Common Stock | A | 55,000 | $0.30 | 440,708 | D | M |
| 02 Apr, 2026 | Jasbir Seehra | Employee Stock Option (Right to Buy) | D | 55,000 | $0.00 | 197,444 | D | M |
| 24 Feb, 2026 | Esther Cho | Employee Stock Option (Right to Buy) | A | 80,000 | $0.00 | 80,000 | D | A |
| 09 Mar, 2026 | Jean Jacques Bienaime | Common Stock | A | 2,000 | $11.21 | 7,450 | D | P |
| 09 Mar, 2026 | Charles W. Newton | Common Stock | A | 13,215 | $0.00 | 13,215 | D | A |
| 09 Mar, 2026 | Charles W. Newton | Common Stock | A | 13,215 | $0.00 | 13,215 | D | A |
| 09 Mar, 2026 | Charles W. Newton | Common Stock | A | 13,215 | $0.00 | 13,215 | D | A |
| 09 Mar, 2026 | Charles W. Newton | Stock Option (Right to Buy) | A | 14,788 | $0.00 | 14,788 | D | A |
| 09 Mar, 2026 | Charles W. Newton | Stock Option (Right to Buy) | A | 14,788 | $0.00 | 14,788 | D | A |
| 09 Mar, 2026 | Charles W. Newton | Stock Option (Right to Buy) | A | 14,788 | $0.00 | 14,788 | D | A |
| 24 Feb, 2026 | Keith Regnante | Employee Stock Option (Right to Buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 24 Feb, 2026 | Lorena Raquel Lerner | Employee Stock Option (Right to Buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 24 Feb, 2026 | Lorena Raquel Lerner | Employee Stock Option (Right to Buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 24 Feb, 2026 | Jasbir Seehra | Employee Stock Option (Right to Buy) | A | 217,000 | $0.00 | 217,000 | D | A |
| 24 Feb, 2026 | Esther Cho | Employee Stock Option (Right to Buy) | A | 80,000 | $0.00 | 80,000 | D | A |
| 24 Feb, 2026 | Keith Regnante | Employee Stock Option (Right to Buy) | A | 60,000 | $0.00 | 60,000 | D | A |
| 24 Feb, 2026 | Lorena Raquel Lerner | Employee Stock Option (Right to Buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 24 Feb, 2026 | Jasbir Seehra | Employee Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 18 Feb, 2026 | Lorena Raquel Lerner | Common Stock | D | 3,873 | $16.35 | 31,127 | D | S |